TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06775717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery with conventional Treatment
Description: This treatment will be given 5 sessions a week in 4 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery with conventional Treatment
Description: This treatment will be given 5 sessions a week in 4 consecutive weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy with conventional Treatment.
Description: This treatment will be given 5 sessions a week in 4 consecutive weeks.
Study: NCT05707429

Intervention type: OTHER
Intervention: The Female Sexual Function Index (FSFI)
Description: The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
Study: NCT06775717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy with conventional Treatment.
Description: This treatment will be given 5 sessions a week in 4 consecutive weeks.
Study: NCT06776159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized injection protocol
Description: Nurses administer LMWH according to the standardized evidence-based protocol.
Study: NCT04854291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of donor FMT
Description: Intracaecal infusion of FMT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Intracaecal infusion of carrier solution
Study: NCT06052306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3546828
Description: Intravenous (IV) infusion on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3546828
Description: Intravenous (IV) infusion on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3546828
Description: Intravenous (IV) infusion on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3546828
Description: Intravenous (IV) infusion on Day 1 of each cycle.
Study: NCT05428566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Description: An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TLC diet
Description: An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber.
Study: NCT04769167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stool and Blood Specimen Collection
Description: Stool and Blood specimens will be collected at 3 designated time points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stool and Blood Specimen Collection
Description: Stool and Blood specimens will be collected at 3 designated time points

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stool and Blood Specimen Collection
Description: Stool and Blood specimens will be collected at 3 designated time points

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stool and Blood Specimen Collection
Description: Stool and Blood specimens will be collected at 3 designated time points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Medical Record Review
Description: Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Medical Record Review
Description: Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up Medical Record Review
Description: Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up Medical Record Review
Description: Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
Study: NCT05490615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Mindfulness
Description: Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
Study: NCT05153161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memesto
Description: Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
Study: NCT06462326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Oral Tablet
Description: 400mg per tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Oral Tablet
Description: 150 mg per tablet
Study: NCT05695365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last \~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
Study: NCT06241326

Intervention type: OTHER
Intervention: Immunotherapy-based Combination Therapies
Description: immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions

Intervention type: OTHER
Intervention: Immunotherapy-based Combination Therapies
Description: immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
Study: NCT06085170

Intervention type: DIAGNOSTIC_TEST
Intervention: Acoustic Analysis by MDVP
Description: Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice

Intervention type: DIAGNOSTIC_TEST
Intervention: Acoustic Analysis by MDVP
Description: Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
Study: NCT05772299

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Er:Yag laser
Description: Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS ultrasound
Description: Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
Study: NCT06109662

Intervention type: DIAGNOSTIC_TEST
Intervention: Cystatin C eGFR
Description: Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cystatin C eGFR
Description: Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cystatin C eGFR
Description: Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cystatin C eGFR
Description: Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.

Intervention type: OTHER
Intervention: Bioimpedance Analysis (Body composition analysis)
Description: Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Intervention type: OTHER
Intervention: Bioimpedance Analysis (Body composition analysis)
Description: Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Intervention type: OTHER
Intervention: Bioimpedance Analysis (Body composition analysis)
Description: Participants will stand on a bioimpedance analysis machine which will measure different components of body composition

Intervention type: OTHER
Intervention: Bioimpedance Analysis (Body composition analysis)
Description: Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
Study: NCT05775809

Intervention type: DRUG
Intervention: selective serotonin reuptake inhibitors
Description: Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded.

Intervention type: DEVICE
Intervention: TMS
Description: TMS are allowed. The method, frequency, and duration of therapy should be recorded.
Study: NCT04698122

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination

Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study: NCT05242419

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection
Description: 0.9% Sodium Chloride Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A Injection
Description: Huperzine A Injection
Study: NCT06646588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: intravenous drip 200mg，day1，once every three weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy synchronised with drugs.
Study: NCT05812547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen
Description: subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose monitoring mobile app
Description: The control group will use a designated glucose monitoring mobile app to record their glucose levels
Study: NCT06090318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: 260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
Study: NCT05314569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine- dexmedetomidine
Description: ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl- midazolam
Description: Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoflurane
Description: Anesthetic inhalational gas
Study: NCT05564949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD
Description: Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
Study: NCT06409026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
Study: NCT06355986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert-based computerized decision support
Description: An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
Study: NCT05642962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertzye
Description: Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertzye
Description: Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
Study: NCT05709834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic training
Description: Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: Patients will receive conventional treatment
Study: NCT05275894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implant hygiene instructions and removal of the prosthesis
Description: Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical peri-implantitis treatment /microsurgery
Description: Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surface decontamination 1(ultrasonic device)
Description: Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surface decontamination 2 (air polishing)
Description: Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surface decontamination 3 (electrolytic cleaning)
Description: Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Metronidazole)
Description: Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modification and polishing of the prosthesis
Description: If necessary, modification and polishing of the prosthesis to make it cleanable.
Study: NCT04798976

Intervention type: DRUG
Intervention: neoadjuvant/adjuvant therapy
Description: chemotherapy/endocrine therapy/surgery/radiotherapy

Intervention type: DRUG
Intervention: neoadjuvant/adjuvant therapy
Description: chemotherapy/endocrine therapy/surgery/radiotherapy
Study: NCT05663294

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beams radiotherapy
Description: External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR.